Descriptive data of components received by control and TRALI patients
| . | Units received by control patients (N = 164) . | Units received by TRALI patients (N = 89) . |
|---|---|---|
| Total no. of units, mean ± SD | 6.43 ± 6.1 | 11 ± 15.1 |
| Total no. of units, median (range) | 3 (1-37) | 4 (1-69) |
| No. of whole blood units, mean ± SD | 0.02 ± 0.22 | 0.13 ± 0.77 |
| No. of whole blood units, median (range) | 0.0 (0.0-2) | 0.0 (0.0-6) |
| No. of RBC units, mean ± SD | 2.52 ± 2.42 | 3.57 ± 4.87 |
| No. of RBC units, median (range) | 2 (0.0-12) | 2 (0.0-25) |
| No. of apheresis platelets, mean ± SD | 0.49 ± 0.779 | 0.91 ± 1.42 |
| No. of apheresis platelets, median (range) | 0.0 (0.0-3) | 0.0 (0.0-7) |
| No. of plasma units, mean ± SD | 2.86 ± 4.35 | 4.69 ± 7.24 |
| No. of plasma units, median (range) | 0.0 (0.0-21) | 2 (0.0-40) |
| No. of cryoprecipitate doses, mean ± SD | 0.53 ± 2.42 | 1.66 ± 4.63 |
| No. of cryoprecipitate doses, median (range) | 0.0 (0.0-20) | 0.0 (0.0-20) |
| Age of RBC units, mean ± SD (N) | 21.5 ± 11 (N = 413) | 21.8 ± 11.4 (N = 318) |
| Age of RBC units, median (range) | 20 (3-42) | 21 (4-42) |
| Age of platelet units, mean ± SD (N) | 4.91 ± 1.11 (N = 81) | 4.99 ± 1.36 (N = 81) |
| Age of platelet units, median (range) | 5 (2-7) | 5 (2-7) |
| . | Units received by control patients (N = 164) . | Units received by TRALI patients (N = 89) . |
|---|---|---|
| Total no. of units, mean ± SD | 6.43 ± 6.1 | 11 ± 15.1 |
| Total no. of units, median (range) | 3 (1-37) | 4 (1-69) |
| No. of whole blood units, mean ± SD | 0.02 ± 0.22 | 0.13 ± 0.77 |
| No. of whole blood units, median (range) | 0.0 (0.0-2) | 0.0 (0.0-6) |
| No. of RBC units, mean ± SD | 2.52 ± 2.42 | 3.57 ± 4.87 |
| No. of RBC units, median (range) | 2 (0.0-12) | 2 (0.0-25) |
| No. of apheresis platelets, mean ± SD | 0.49 ± 0.779 | 0.91 ± 1.42 |
| No. of apheresis platelets, median (range) | 0.0 (0.0-3) | 0.0 (0.0-7) |
| No. of plasma units, mean ± SD | 2.86 ± 4.35 | 4.69 ± 7.24 |
| No. of plasma units, median (range) | 0.0 (0.0-21) | 2 (0.0-40) |
| No. of cryoprecipitate doses, mean ± SD | 0.53 ± 2.42 | 1.66 ± 4.63 |
| No. of cryoprecipitate doses, median (range) | 0.0 (0.0-20) | 0.0 (0.0-20) |
| Age of RBC units, mean ± SD (N) | 21.5 ± 11 (N = 413) | 21.8 ± 11.4 (N = 318) |
| Age of RBC units, median (range) | 20 (3-42) | 21 (4-42) |
| Age of platelet units, mean ± SD (N) | 4.91 ± 1.11 (N = 81) | 4.99 ± 1.36 (N = 81) |
| Age of platelet units, median (range) | 5 (2-7) | 5 (2-7) |
In multivariate analysis, the risk of increased no. of involved units was accounted for by the antibody and patient risk factors shown in Table 12 (“Risk of greater number of transfusions”).